Wendy Noble

Wendy Noble

Auto-generated profile, based on publicly available information

Wendy Noble

University of Exeter, UK

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 1999 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
SDStephen R. Durham
Stephen R. Durham
SWSamantha M. Walker
Samantha M. Walker
EVEva-Maria Varga
Eva-Maria Varga
MJMikila R. Jacobson
Mikila R. Jacobson
FOFiona O'BRien
Fiona O'BRien
KNKayhan T. Nouri-Aria
Kayhan T. Nouri-Aria
Pollen immunotherapy is effective in selected patients with IgE-mediated seasonal allergic rhinitis, although it is questionable whether there is long-term benefit after the discontinuation of treatment. We conducted a randomized, double-blind, placebo-controlled trial of the discontinuation of immunotherapy for grass-pollen allergy in patients in whom three to four years of this treatment had previously been shown to be effective. During the three years of this trial, primary outcome measures were scores for seasonal symptoms and the use of rescue medication. Objective measures included the immediate conjunctival response and the immediate and late skin responses to allergen challenge. Cutaneous-biopsy specimens obtained 24 hours after intradermal allergen challenge were examined for T-cell infiltration and the presence of cytokine-producing T helper cells (TH2 cells) (as evidenced by the presence of interleukin-4 messenger RNA). A matched group of patients with hay fever who had not received immunotherapy was followed as a control for the natural course of the disease. Scores for seasonal symptoms and the use of rescue antiallergic medication, which included short courses of prednisolone, remained low after the discontinuation of immunotherapy, and there was no significant difference between patients who continued immunotherapy and those who discontinued it. Symptom scores in both treatment groups (median areas under the curve in 1995, 921 for continuation of immunotherapy and 504 for discontinuation of immunotherapy; P=0.60) were markedly lower than those in the group that had not received immunotherapy (median value in 1995, 2863). Although there was a tendency for immediate sensitivity to allergen to return late after discontinuation, there was a sustained reduction in the late skin response and associated CD3+ T-cell infiltration and interleukin-4 messenger RNA expression. Immunotherapy for grass-pollen allergy for three to four years induces prolonged clinical remission accompanied by a persistent alteration in immunologic reactivity.

6 April 2017 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
TGTong Guo
Tong Guo
WNWendy Noble
Wendy Noble
DHDiane P. Hanger
Diane P. Hanger
Tau is well established as a microtubule-associated protein in neurons. However, under pathological conditions, aberrant assembly of tau into insoluble aggregates is accompanied by synaptic dysfunction and neural cell death in a range of neurodegenerative disorders, collectively referred to as tauopathies. Recent advances in our understanding of the multiple functions and different locations of tau inside and outside neurons have revealed novel insights into its importance in a diverse range of molecular pathways including cell signalling, synaptic plasticity, and regulation of genomic stability. The present review describes the physiological and pathophysiological properties of tau and how these relate to its distribution and functions in neurons. We highlight the post-translational modifications of tau, which are pivotal in defining and modulating tau localisation and its roles in health and disease. We include discussion of other pathologically relevant changes in tau, including mutation and aggregation, and how these aspects impinge on the propensity of tau to propagate, and potentially drive neuronal loss, in diseased brain. Finally, we describe the cascade of pathological events that may be driven by tau dysfunction, including impaired axonal transport, alterations in synapse and mitochondrial function, activation of the unfolded protein response and defective protein degradation. It is important to fully understand the range of neuronal functions attributed to tau, since this will provide vital information on its involvement in the development and pathogenesis of disease. Such knowledge will enable determination of which critical molecular pathways should be targeted by potential therapeutic agents developed for the treatment of tauopathies.

1 March 2009 in Trends in Molecular Medicine
Verified
Journal Article
Closed access
DHDiane P. Hanger
Diane P. Hanger
BABrian H. Anderton
Brian H. Anderton
WNWendy Noble
Wendy Noble

15 February 2013 in EMBO Reports
Verified
Journal Article
Open access
PDF file
APAmy M Pooler
Amy M Pooler
EPEmma C Phillips
Emma C Phillips
DLDawn H W Lau
Dawn H W Lau
WNWendy Noble
Wendy Noble
DHDiane P Hanger
Diane P Hanger
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

2 May 2005 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
WNWendy Noble
Wendy Noble
EPEmmanuel Planel
Emmanuel Planel
CZCindy Zehr
Cindy Zehr
VOVicki Olm
Vicki Olm
JMJordana Meyerson
Jordana Meyerson
KDKaren Duff
Karen Duff
Neurofibrillary tangles composed of hyperphosphorylated, aggregated tau are a common pathological feature of tauopathies, including Alzheimer's disease. Abnormal phosphorylation of tau by kinases or phosphatases has been proposed as a pathogenic mechanism in tangle formation. To investigate whether kinase inhibition can reduce tauopathy and the degeneration associated with itin vivo, transgenic mice overexpressing mutant human tau were treated with the glycogen synthase kinase-3 (GSK-3) inhibitor lithium chloride. Treatment resulted in significant inhibition of GSK-3 activity. Lithium administration also resulted in significantly lower levels of phosphorylation at several epitopes of tau known to be hyperphosphorylated in Alzheimer's disease and significantly reduced levels of aggregated, insoluble tau. Administration of a second GSK-3 inhibitor also correlated with reduced insoluble tau levels, supporting the idea that lithium exerts its effect through GSK-3 inhibition. Levels of aggregated tau correlated strongly with degree of axonal degeneration, and lithium-chloride-treated mice showed less degeneration if administration was started during early stages of tangle development. These results support the idea that kinases are involved in tauopathy progression and that kinase inhibitors may be effective therapeutically.

1 May 2003 in Neuron
Verified
Journal Article
Closed access
WNWendy Noble
Wendy Noble
VOVicki Olm
Vicki Olm
KTKazuyuki Takata
Kazuyuki Takata
ECEvelyn Casey
Evelyn Casey
OMO Mary
O Mary
KDKaren Duff
Karen Duff